
Approving Apheresis and high risk immune effector cell trials

Lead Organisation: iMATCH

Author: The Christie NHS Foundation Trust

Version Number: 3.0

Finalisation Date: 05/23

End user rights:

This document is shared with permission for re-use to distribute, remix, adapt, and build upon the material in any medium or format for non-commercial purposes only, so long as the attributions listed below are given.

Attributions: The Christie NHS Foundation Trust

This document is made available under a Creative Commons Attribution-NonCommercial 4.0 International License as described here: <https://creativecommons.org/licenses/by-nc/4.0/>

The information, materials and any opinions contained in this document are provided for general information and educational purposes only, are not intended to constitute legal, medical or other professional advice and should not be relied on or treated as a substitute for specific advice relevant to particular circumstances. Although we make all reasonable efforts to ensure the information is up to date, we make no representations, warranties or guarantees in that regard. In no event shall the creator(s) be liable for any direct, indirect, special, consequential or other claims, losses or damages that are related to the use or reliance whatsoever in the content of the document or any part thereof, except to the extent that such liability cannot be excluded by law. We do not seek to exclude or limit in any way our liability to the user for personal injury or death caused as a result of our negligence or seek to exclude or limit our liability for fraud or fraudulent misrepresentation by us.

We reserve the right to make changes and improvements to any information contained within this document, at any time and without notice. Where this document contains hyperlinks to other websites operated by parties not connected to us, such hyperlinks are provided for your reference only. We do not control such websites and are not responsible for their contents.

The inclusion of hyperlinks from this document or the website to such websites does not imply any endorsement of the material on such websites or any association with their operators. We accept no responsibility of any nature whatsoever for linked web sites or any information contained in them.

Funded by



Coordinated by





| | |
|--|---------------------------------|
| Approving Apheresis and high risk immune effector cell trials | |
| Author | |
| Revision | 3.0 |
| Changes from previous Version | Minor changes and format update |

Table of Contents

| | |
|---|---|
| 1.0 Introduction & Scope | 3 |
| 2.0 Responsibilities | 3 |
| 3.0 Objectives | 3 |
| 4.0 Flowchart | 5 |
| 5.0 Training and Competence | 5 |
| 7.0 Monitoring Compliance | 5 |
| 8.0 Dissemination/ Distribution | 6 |
| 9.0 References and Related Forms, Labels, Policies and Procedures | 6 |
| 10.0 Approval Process & Review Process | 6 |

| | | |
|---|--------------------------|-------------|
| PRINTED COPIES MAY NOT BE THE MOST CURRENT VERSION OF THIS DOCUMENT. ALWAYS REFER TO Q PULSE FOR THE MOST UP TO DATE VERSION | | |
| Document Name: Approving Apheresis and High Risk immune effector cell trials | | Version 3.0 |
| Index Number QM 11 | | Author: |
| Effective Date: May 2023 | Review Date: See Q Pulse | Page 2 of 7 |



1.0 Introduction & Scope

As part of the process to achieve capacity and capability confirmation from the Christie Research Division for a clinical trial, the Cellular Therapy and Transplant Programme must internally approve relevant aspects of each trial involving apheresis and/or high risk immune effector cell therapy. Ensuring any differences between the trial protocol and Programme SOPs and policies are highlighted and discussed to ascertain whether the trial can be facilitated.

This SOP aims to ensure that proposed trial protocols requiring access to the Cellular Therapy and Transplant Programme services are reviewed by the appropriate staff prior to being authorised to open.

2.0 Responsibilities

The Quality Manager and Ward Nursing Leads are responsible for ensuring staff who are required to carry out activities described in this document receive a copy via the Q Pulse document distribution system.

All staff who are required to undertake activities described in this document must read and acknowledge receipt of this document, and where training is required shall not undertake described activities unsupervised until relevant training has been delivered.

3.0 Objectives

Once the trial sponsor has provided the trial specific procedure manual/s (e.g. Investigator Brochure, Apheresis Manual, Lab Manual, Cell Handling Manual, Final Product Manual etc.) these must be forwarded to the appropriate staff for review by the Study Delivery Team:

Any procedural documents relating to Apheresis must be sent to the Lead Nurse for Apheresis.

Any procedural documents relating to the Stem Cell Lab must be sent to the Stem Cell Laboratory Manager.

Any procedural documents relating to the Palatine Ward (e.g. infusion of cells) must be sent to the Palatine Ward Senior Clinical Practice Facilitator.

Any procedural documents relating to the Clinical Research Facility (CRF) (e.g. infusion of cells) must be sent to the CRF Senior Clinical Practice Facilitator.

PRINTED COPIES MAY NOT BE THE MOST CURRENT VERSION OF THIS DOCUMENT. ALWAYS REFER TO Q PULSE FOR THE MOST UP TO DATE VERSION

Document Name: Approving Apheresis and High Risk immune effector cell trials

Version 3.0

Index Number QM 11

Author:

Effective Date: May 2023

Review Date: See Q Pulse

Page 3 of 7



Costings sheet/financial agreement to be sent to the Haematology Clinical Services Manager.

The procedural manuals will be reviewed to ascertain any differences between the trial protocol and standard practice as defined by Programme SOPs and policies.

Once the review of the trial procedural documents has taken place the trials are presented at the monthly CTO meeting. Within this meeting an overview of the trial and any discrepancies between the protocol and programme SOPs and policies are presented and discussed. A decision will be minuted as to whether the trial protocol can be facilitated or whether there are further discussions required with the trial team and sponsor. If there is urgency in obtaining trial approval the trial can be approved outside the meeting and noted at the next CTO meeting.

If the clinical trial involves different processes than the standard programme procedures the trial must be reviewed at the CTO meeting and one of the following options will be agreed;

1. Programme SOPs should be changed in line with the trial procedures or;
2. It is acceptable for the programme to deviate from standard practices or;
3. The procedures within the trial are unsafe/impracticable and therefore the trial cannot be approved unless the trial sponsor agrees to alter the protocol in line with the programme procedures.

In the event of the second option being agreed the procedures will need to be documented in the delineation of responsibilities document that will be written for each trial/trial specific crib sheet. All staff involved in the new procedures must receive the relevant training.

Once all staff groups are satisfied with the trial procedures and that the programme has the capacity to deliver the trial the Programme Director and clinical services manager can authorise for those sections of the trial to be approved. This will be fed back to the trial team by the Quality Manager. Escalation of issues if a solution is not found is done in the monthly Quality Management Meeting (QMM).

If option three is agreed and the trial cannot be supported this will be fed back to the research team, Research ATMP committee and ATMP Board with justification as to why the study can't be supported.


Once the relevant cellular therapy and transplant programme services are approved the trial team with input from the relevant service team (e.g. apheresis, stem cell lab, ward/CRF staff etc.) must complete and upload to Q-Pulse a delineation of responsibilities (AGR-1) prior to the study opening for recruitment. The apheresis

| | | |
|---|--------------------------|-------------|
| PRINTED COPIES MAY NOT BE THE MOST CURRENT VERSION OF THIS DOCUMENT. ALWAYS REFER TO Q PULSE FOR THE MOST UP TO DATE VERSION | | |
| Document Name: Approving Apheresis and High Risk immune effector cell trials | | Version 3.0 |
| Index Number QM 11 | | Author: |
| Effective Date: May 2023 | Review Date: See Q Pulse | Page 4 of 7 |



team will also complete a trial specific crib sheet which clearly defines the procedures required; these will be stored in the apheresis room in Department 26.

4.0 Flowchart



5.0 Training and Competence

Prior to implementation of any new or revised procedure there shall be a review and if considered appropriate training and competency shall be delivered prior to implementation of the procedure.

7.0 Monitoring Compliance

Compliance to this document will be monitored by a combination of audit where applicable, non-conformance monitoring and Datix incident reporting.

| | | |
|---|--------------------------|-------------|
| PRINTED COPIES MAY NOT BE THE MOST CURRENT VERSION OF THIS DOCUMENT. ALWAYS REFER TO Q PULSE FOR THE MOST UP TO DATE VERSION | | |
| Document Name: Approving Apheresis and High Risk immune effector cell trials | | Version 3.0 |
| Index Number QM 11 | | Author: |
| Effective Date: May 2023 | Review Date: See Q Pulse | Page 5 of 7 |



8.0 Dissemination/ Distribution

This document will be distributed to staff members who need visibility of the document via Q Pulse.

9.0 References and Related Forms, Labels, Policies and Procedures

The Christie Research Division process for capacity and capability is defined in:

- R&D 001.000 - Research Study Set Up – Capacity and Capability Process
- R&D 001.002 Capacity and Capability Assessment
- Trials Spreadsheet

10.0 Approval Process & Review Process

All new procedures are approved by the Clinical Program Director or approved designate before implementation of the procedure.

Revisions to existing procedures will be approved by the Clinical Director or approved designate prior to implementation.

Procedures will be reviewed every 2 years as a minimum

PRINTED COPIES MAY NOT BE THE MOST CURRENT VERSION OF THIS DOCUMENT. ALWAYS REFER TO Q PULSE FOR THE MOST UP TO DATE VERSION

| | |
|--|--------------------------|
| Document Name: Approving Apheresis and High Risk immune effector cell trials | Version 3.0 |
| Index Number QM 11 | Author: |
| Effective Date: May 2023 | Review Date: See Q Pulse |
| | Page 6 of 7 |



PRINTED COPIES MAY NOT BE THE MOST CURRENT VERSION OF THIS DOCUMENT. ALWAYS REFER TO Q PULSE FOR THE MOST UP TO DATE VERSION

| | | |
|--|--------------------------|-------------|
| Document Name: Approving Apheresis and High Risk immune effector cell trials | Version 3.0 | |
| Index Number QM 11 | Author: | |
| Effective Date: May 2023 | Review Date: See Q Pulse | Page 7 of 7 |